6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis

키워드

참고문헌 (41)

1. Emberton M, "Benign prostatic hyperplasia : a progressive disease of aging men", Urology, 61, pp.267~273 (2003)
2. O'Leary MP, "Lower urinary tract symptoms", benign prostatic hyperplasia : maintaining symptom control and reducing complications, 2003, pp.62, 15~23
3. Keledjian K, "Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin", Prostate, 48, pp.71~78 (2001)
4. Carson C 3rd, "The role of dihydrotestosterone in benign prostatic hyperplasia", Urology, 61, pp.2~7 (2003)
5. Zaman Huri H, "Drug-related problems in patients with benign prostatic hyperplasia : a cross sectional retrospective study", PLoS One, 9, pp.e86215~ (2014)
6. DuBeau CE, "Controversies in the diagnosis and management of benign prostatic hypertrophy", Adv Intern Med, 37, pp.55~83 (1992)
7. 정경진, "Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms", International Neurourology Journal, 21(2), pp.97~101 (2017), 대한배뇨장애요실금학회
8. McNeal JE, "Origin and evolution of benign prostatic enlargement", Invest Urol, 15, pp.340~345 (1978)
9. Lekas A, "The expression of hypoxia-inducible factor-1alpha(HIF-1alpha)and angiogenesis markers in hyperplastic and malignant prostate tissue", Anticancer Res, 26, pp.2989~2993 (2006)
10. Wu F, "Elevated expression of HIF-lalpha in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia", Oncotarget, 7, pp.12053~12062 (2016)
11. Pareek G, "The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density : a possible mechanism for decreased prostatic bleeding in treated patients", J Urol, 169, pp.20~23 (2003)
12. Stefanou D, "Expression of vascular endothelial growth factor(VEGF)and association with microvessel density in benign prostatic hyperplasia and prostate cancer", In Vivo, 18, pp.155~160 (2004)
13. Aweimer A, "Regulation of soluble VEGFR-2 secreted by microvascular endothelial cells derived from human BPH", Prostate Cancer Prostatic Dis, 15, pp.157~164 (2012)
14. Berger AP, "Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia", Prostate, 57, pp.57~65 (2003)
15. Jackson MW, "Vascular endothelial growth factor(VEGF)expression in prostate cancer and benign prostatic hyperplasia", J Urol, 157, pp.2323~2328 (1997)
16. Lekas AG, "Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia", Urology, 68, pp.436~441 (2006)
17. Sordello S, "Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens", Biochem Biophys Res Commun, 251, pp.287~290 (1998)
18. Levine AC, "Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts", Endocrinology, 139, pp.4672~4678 (1998)
19. Foo KT, "Pathophysiology of clinical benign prostatic hyperplasia", Asian J Urol, 4, pp.152~157 (2017)
20. Wen J, "Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells", Prostate, 73, pp.1069~1081 (2013)
21. Wu S, "Annotation and structural analysis of sialylated human milk oligosaccharides", J Proteome Res, 10, pp.856~868 (2011)
22. Yonekawa T, "Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice", Brain, 137, pp.2670~2679 (2014)
23. Bode L, "Human milk oligosaccharides : every baby needs a sugar mama", Glycobiology, 22, pp.1147~1162 (2012)
24. Chung TW, "Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression", Oncotarget, 8, pp.58152~58162 (2017)
25. Vaarala MH, "Identification of androgen-regulated genes in human prostate", Mol Med Rep, 6, pp.466~472 (2012)
26. 박성아, "Structure and function of vascular endothelial growth factor and its receptor system", BMB Reports, 51(2), pp.73~78 (2018), 생화학분자생물학회
27. Li J, "Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms", PLoS One, 13, pp.e0191469~ (2018)
28. Kim SK, "Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model", BMC Complement Altern Med, 15, pp.380~ (2015)
29. Minutoli L, "Serenoa repens, lycopene and selenium : a triple therapeutic approach to manage benign prostatic hyperplasia", Curr Med Chem, 20, pp.1306~1312 (2013)
30. Said MM, "Flaxseed suppressed prostatic epithelial proliferation in a rat model of benign prostatic hyperplasia", J Toxicol Environ Health A, 78, pp.453~465 (2015)
31. Kim JH, "Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia : A meta-analysis", PLoS One, 13, pp.e0203479~ (2018)
32. Jun JEJ, "5alpha-Reductase inhibitors for treatment of benign prostatic hyperplasia : A systematic review and metaanalysis", Can J Hosp Pharm, 70, pp.113~119 (2017)
33. Thomas D, "Emerging drugs for the treatment of benign prostatic hyperplasia", Expert Opin Emerg Drugs, 22, pp.201~212 (2017)
34. Bostwick DG, "Microvessel density in prostate cancer : prognostic and therapeutic utility", Semin Urol Oncol, 16, pp.118~123 (1998)
35. Padhani AR, "Angiogenesis imaging in the management of prostate cancer", Nat Clin Pract Urol, 2, pp.596~607 (2005)
36. Ravindranath N, "Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate", J Androl, 22, pp.432~443 (2001)
37. ten Bruggencate SJ, "Functional role and mechanisms of sialyllactose and other sialylated milk oligosaccharides", Nutr Rev, 72, pp.377~389 (2014)
38. Godoy A, "Androgen deprivation induces rapid involution and recovery of human prostate vasculature", Am J Physiol Endocrinol Metab, 300, pp.E263~275 (2011)
39. Chung HK, "Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis", J Cell Biol, 216, pp.149~165 (2017)
40. Ryu D, "A SIRT7-dependent acetylation switch of GABPbeta1 controls mitochondrial function", Cell Metab, 20, pp.856~869 (2014)
41. Chung TW, "CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth", J Mol Med(Berl), 91, pp.271~282 (2013)

관련 논문AI추천